Eric Topol on Twitter: “New reports on transmissibility and immune evasiveness for delta (B.1.617.2) lead to an update of this Table of the variants and key properties https://t.co/nGzEa39eF4” / Twitter. (n.d.). Retrieved June 5, 2021, from https://twitter.com/EricTopol/status/1400590583274426370
- Jun 2021
-
twitter.com twitter.com
-
www.theguardian.com www.theguardian.com
-
UK tightens borders and travel rules as variants spark new alarm | Coronavirus | The Guardian. (n.d.). Retrieved June 5, 2021, from https://www.theguardian.com/world/2021/jun/03/concern-over-delta-covid-variant-tightens-borders-of-uk
-
-
en.wikipedia.org en.wikipedia.org
-
The terms autonym and xenonym also had different applications,[3] thus leaving endonym and exonym as the preferred forms.
-
-
www.reuters.com www.reuters.com
-
UK health minister confirms talks with AstraZeneca over new variant vaccines. (2021, June 2). Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/uk-health-minister-confirms-talks-with-astrazeneca-over-new-variant-vaccines-2021-06-02/
-
-
www.bmj.com www.bmj.com
-
Iacobucci, G. (2021). Covid-19: Local councils initiate surge vaccination to tackle B.1.617.2 variant. BMJ, 373, n1361. https://doi.org/10.1136/bmj.n1361
-
-
-
Mahase, E. (2021). Covid-19: Is it safe to lift all restrictions in England from 21 June? BMJ, 373, n1399. https://doi.org/10.1136/bmj.n1399
-
-
www.bmj.com www.bmj.com
-
Mahase, E. (2021). Covid-19: Government faces legal challenge over alleged suppression of school data. BMJ, 373, n1408. https://doi.org/10.1136/bmj.n1408
-
-
docs.gitlab.com docs.gitlab.com
-
We want the GraphQL API to be the primary means of interacting programmatically with GitLab. To achieve this, it needs full coverage - anything possible in the REST API should also be possible in the GraphQL API.
-
- May 2021
-
-
Mallapaty, S. (2021). India’s neighbours race to sequence genomes as COVID surges. Nature, 593(7860), 485–486. https://doi.org/10.1038/d41586-021-01287-2
-
-
twitter.com twitter.com
-
Prof. Christina Pagel on Twitter: “So Hancock confirms that B.1.617.2 (‘India’ variant) is now dominant in England. Harries says we must remain ‘vigilant’. What does vigilant even mean? That we watch very carefully as a new, more dangerous, variant takes over cos it was so fun last time? Yeah, I’m pissed off” / Twitter. (n.d.). Retrieved May 28, 2021, from https://twitter.com/chrischirp/status/1397951741283405825
-
-
-
Here’s why schools should be on alert over new coronavirus variants—CNN. (n.d.). Retrieved May 28, 2021, from https://edition.cnn.com/2021/05/26/world/coronavirus-variant-schools-cmd-intl/index.html
-
-
blogs.bmj.com blogs.bmj.com
-
The UK’s coronavirus policy still places too much responsibility—And blame—On the public—The BMJ. (n.d.). Retrieved May 27, 2021, from https://blogs.bmj.com/bmj/2021/05/26/the-uks-coronavirus-policy-still-places-too-much-responsibility-and-blame-in-the-hands-of-the-public/?utm_source=twitter&utm_medium=social&utm_term=hootsuite&utm_content=sme&utm_campaign=usage
-
-
www.bmj.com www.bmj.com
-
Iacobucci, G. (2021). Covid-19: Single vaccine dose is 33% effective against variant from India, data show. BMJ, n1346. https://doi.org/10.1136/bmj.n1346
-
-
-
Mallapaty, S. (2021). Scientists zero in on long-sought marker of COVID-vaccine efficacy. Nature, d41586-021-01372–01376. https://doi.org/10.1038/d41586-021-01372-6
-
-
-
Adam, D. (2021). What scientists know about new, fast-spreading coronavirus variants. Nature. https://doi.org/10.1038/d41586-021-01390-4
-
-
www.nature.com www.nature.com
-
Richardson, H. (2021). How waste water is helping South Africa fight COVID-19. Nature, 593(7860), 616–617. https://doi.org/10.1038/d41586-021-01399-9
-
-
www.theguardian.com www.theguardian.com
-
No 10 ‘tried to block’ data on spread of new Covid variant in English schools | Coronavirus | The Guardian. (n.d.). Retrieved May 24, 2021, from https://www.theguardian.com/world/2021/may/22/no-10-tried-to-block-data-on-spread-of-new-covid-variant-in-english-schools
-
-
www.theguardian.com www.theguardian.com
-
Ministers ‘failed to act on Bedford Covid variant surge for two weeks’ | Coronavirus | The Guardian. (n.d.). Retrieved May 24, 2021, from https://www.theguardian.com/world/2021/may/23/ministers-failed-to-act-on-bedford-covid-variant-surge-for-two-weeks
Tags
- variant
- Bedford
- wastewater
- Indian variant
- is:news
- government
- travel ban
- detection
- response
- COVID-19
- epidemiology
- prevention
- intervention
- sewage
- UK
- lang:en
Annotators
URL
-
-
www.bbc.co.uk www.bbc.co.uk
-
Covid: India tells social media firms to remove ‘India variant’ from content. (2021, May 22). BBC News. https://www.bbc.com/news/world-asia-india-57213046
-
-
www.thelancet.com www.thelancet.com
-
Ramanathan, M., Ferguson, I. D., Miao, W., & Khavari, P. A. (2021). SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00262-0
-
-
www.biorxiv.org www.biorxiv.org
-
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. BioRxiv, 2021.05.19.444825. https://doi.org/10.1101/2021.05.19.444825
-
-
twitter.com twitter.com
-
John Burn-Murdoch. (2021, May 7). NEW: time for a proper thread on B.1.617.2, the subtype of the Indian variant that has been moved to ‘variant of concern’ today by Public Health England. First, it’s clear case numbers from this lineage are growing faster than other imported variants have done in the UK. https://t.co/hUUzBvCsY1 [Tweet]. @jburnmurdoch. https://twitter.com/jburnmurdoch/status/1390666071724765185
-
-
twitter.com twitter.com
-
Prof. Christina Pagel on Twitter: “SHORT THREAD: I was on Sky News earlier where I explained why I thought test 4 (new variant test) for the next stage of the roadmap had not been met, because of B.1.617.2 (the so called ‘Indian’ variant of concern). 1/5 https://t.co/0O3dL2saOR” / Twitter. (n.d.). Retrieved May 17, 2021, from https://twitter.com/chrischirp/status/1392927819504701441
-
-
www.theguardian.com www.theguardian.com
-
the Guardian. “How Good Are We at Predicting the Pandemic? | David Spiegelhalter & Anthony Masters,” May 9, 2021. http://www.theguardian.com/theobserver/commentisfree/2021/may/09/how-good-are-we-at-predicting-pandemic.
-
-
www.nature.com www.nature.com
-
Mallapaty, S. (2021). How a worrisome coronavirus variant spread unnoticed. Nature. https://doi.org/10.1038/d41586-021-01285-4
-
-
twitter.com twitter.com
-
Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422
-
-
-
Government to launch 40,000 person daily contact testing study. (n.d.). GOV.UK. Retrieved 13 May 2021, from https://www.gov.uk/government/news/government-to-launch-40000-person-daily-contact-testing-study
-
-
twitter.com twitter.com
-
Dr. Tom Frieden. (2021, April 30). Globally, the end of the pandemic isn’t near. More than a million lives depend on improving our response quickly. Don’t be blinded by the light at the end of the tunnel. There isn’t enough vaccine and the virus is gathering strength & speed. Global cooperation is crucial. 1/ [Tweet]. @DrTomFrieden. https://twitter.com/DrTomFrieden/status/1388172436999376899
-
-
twitter.com twitter.com
-
ReconfigBehSci. (2021, May 1). RT @GuptaR_lab: Given the dire situation in India and questions regarding the new variant B.1.617, the so called ‘Double Mutant’ we are sha… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1388915829383720961
-
-
www.scientificamerican.com www.scientificamerican.com
-
Brazil’s Pandemic Is a “Biological Fukushima” That Threatens the Entire Planet—Scientific American. (n.d.). Retrieved May 12, 2021, from https://www.scientificamerican.com/article/brazils-pandemic-is-a-lsquo-biological-fukushima-rsquo-that-threatens-the-entire-planet/
-
-
www.newscientist.com www.newscientist.com
-
Vaughan, A. (2021, May 10). Indian coronavirus variant in the UK seems to be more transmissible. New Scientist. https://www.newscientist.com/article/2277153-indian-coronavirus-variant-in-the-uk-seems-to-be-more-transmissible/
-
-
www.theguardian.com www.theguardian.com
-
the Guardian. “Brazil Variant Evaded up to 61% of Immunity in Previous Covid Cases,” March 2, 2021. http://www.theguardian.com/world/2021/mar/02/brazil-variant-evaded-immunity-previous-covid-cases.
-
-
www.theguardian.com www.theguardian.com
-
New concerns as Indian Covid variant clusters found across England | Coronavirus | The Guardian. (n.d.). Retrieved May 7, 2021, from https://www.theguardian.com/world/2021/may/06/new-concerns-indian-covid-variant-clusters-found-across-england-ongoing-risk-high
-
-
dash.harvard.edu dash.harvard.edu
-
Kissler, S., Fauver, J. R., Mack, C., Tai, C. G., Breban, M. I., Watkins, A. E., Samant, R. M., Anderson, D. J., Ho, D. D., Grubaugh, N. D., & Grad, Y. (2021). Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. https://dash.harvard.edu/handle/1/37366884
-
-
www.theguardian.com www.theguardian.com
-
The UK has record death tolls, yet still the government has no clear Covid strategy | Helen Ward. (2021, January 21). The Guardian. http://www.theguardian.com/commentisfree/2021/jan/21/uk-record-death-tolls-no-clear-covid-strategy
-
-
www.thelancet.com www.thelancet.com
-
Diseases, T. L. I. (2021). An exceptional vaccination policy in exceptional circumstances. The Lancet Infectious Diseases, 21(2), 149. https://doi.org/10.1016/S1473-3099(21)00008-6
-
-
virological.org virological.org
-
Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: Preliminary findings - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology. (2021, January 25). Virological. https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586/2
-
-
twitter.com twitter.com
-
Eric Topol. (2021, February 17). New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines https://t.co/2N7eKDllso [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1362160675913568256
-
-
www.nytimes.com www.nytimes.com
-
Anthes, E. (2021, May 5). Pfizer-BioNTech Vaccine is Highly Effective Against Variants, Studies Find. The New York Times. https://www.nytimes.com/2021/05/05/health/coronavirus-pfizer-vaccine-variants.html
-
-
www.nytimes.com www.nytimes.com
-
Mandavilli, A. (2021, May 3). Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe. The New York Times. https://www.nytimes.com/2021/05/03/health/covid-herd-immunity-vaccine.html
-
-
absolutelymaybe.plos.org absolutelymaybe.plos.org
-
Variants, 3 New Covid Vaccines, and Contested Efficacy Claims: A Month of Seismic Shifts and Confusion. (2021, January 31). Absolutely Maybe. https://absolutelymaybe.plos.org/2021/01/31/variants-3-new-covid-vaccines-and-contested-efficacy-claims-a-month-of-seismic-shifts-and-confusion/
-
-
-
NERVTAG paper on COVID-19 variant of concern B.1.1.7. (n.d.). GOV.UK. Retrieved March 1, 2021, from https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117
-
-
www.lrb.co.uk www.lrb.co.uk
-
Beale, R. (2021, February 19). Eeek! London Review of Books, 43(05). https://www.lrb.co.uk/the-paper/v43/n05/rupert-beale/eeek
-
-
science.sciencemag.org science.sciencemag.org
-
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. da S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., Hulswit, R. J. G., Franco, L. A. M., Ramundo, M. S., Jesus, J. G. de, Andrade, P. S., Coletti, T. M., Ferreira, G. M., Silva, C. A. M., Manuli, E. R., … Sabino, E. C. (2021). Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. https://doi.org/10.1126/science.abh2644
-
-
www.ox.ac.uk www.ox.ac.uk
-
ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults | University of Oxford. (n.d.). Retrieved February 18, 2021, from https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection
-
-
www.reuters.com www.reuters.com
-
Staff, R. (2021, February 6). AstraZeneca thinks shot can stop severe disease from South Africa COVID variant. Reuters. https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-respon-idUKKBN2A60S2
-
-
www.wsj.com www.wsj.com
-
Steinhauser, G. (2021, February 7). Rollout of AstraZeneca Covid-19 Vaccine Halted in South Africa After Study. Wall Street Journal. https://www.wsj.com/articles/astrazeneca-vaccine-doesnt-protect-against-mild-and-moderate-cases-from-south-africa-strain-11612700385
-
-
papers.ssrn.com papers.ssrn.com
-
Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B. J., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E., Collins, A. M., Cox, T., Darton, T., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K., Flaxman, A., … Group, O. C. V. T. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (SSRN Scholarly Paper ID 3779160). Social Science Research Network. https://doi.org/10.2139/ssrn.3779160
-
-
www.newscientist.com www.newscientist.com
-
Lu, D. (n.d.). Australia clamps down in response to cases of UK coronavirus variant. New Scientist. Retrieved February 23, 2021, from https://www.newscientist.com/article/2264588-australia-clamps-down-in-response-to-cases-of-uk-coronavirus-variant/
-
-
www.nytimes.com www.nytimes.com
-
Stolberg, S. G., & Zimmer, C. (2021, April 7). More Contagious Virus Variant Is Now Dominant in U.S., C.D.C. Chief Says. The New York Times. https://www.nytimes.com/2021/04/07/us/politics/coronavirus-variants-cdc.html
-
-
twitter.com twitter.com
-
ReconfigBehSci. (2021, April 18). RT @jcbarret: A few thoughts on the B.1.617 variant, first seen in India in late 2020, recently seen in >100 cases in the UK, and very much… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1384128233348558856
-
- Apr 2021
-
www.theguardian.com www.theguardian.com
-
Roy, A. (2021, April 29). ‘We are witnessing a crime against humanity’: Arundhati Roy on India’s Covid catastrophe. The Guardian. https://www.theguardian.com/news/2021/apr/28/crime-against-humanity-arundhati-roy-india-covid-catastrophe
-
-
twitter.com twitter.com
-
Eric Topol on Twitter: “The variants of concern/interest fall into a spectrum of immune evasiveness, w/ B.1.351 being most; B.1.1.7, B.1.429 least. This property pertains to potential for reinfection & some reduction in vaccine efficacy My prelim estimates based on publications/preprints, subject to Δ https://t.co/fQZwBCUEGS” / Twitter. (n.d.). Retrieved April 28, 2021, from https://twitter.com/EricTopol/status/1380203664317456385
-
-
twitter.com twitter.com
-
ReconfigBehSci. (2021, April 13). RT @JoshBiostats: Important comment by @_nickdavies here: New studies are compatible with B.1.1.7 having higher severity because new studie… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1381927390633410562
-
-
investors.modernatx.com investors.modernatx.com
-
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day. (2021, April 13). Moderna, Inc. https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-and-supply-updates-covid-19-vaccine
Tags
- press release
- is:webpage
- variant
- vaccination
- antibody
- clinical
- booster
- biotechnology
- COVID-19
- supply
- efficacy
- dose
- moderna
- data
- global
- lang:en
Annotators
URL
-
-
www.propublica.org www.propublica.org
-
Chen, C. (2021, April 14). A Tiny Number of People Will Be Hospitalized Despite Being Vaccinated. We Have to Learn Why. ProPublica. https://www.propublica.org/article/a-tiny-number-of-people-will-be-hospitalized-despite-being-vaccinated-we-have-to-learn-why?token=4HsRcuNGpEdmAeWz4oEu5Cr56zj5_5OE
-
-
www.thelancet.com www.thelancet.com
-
Tan, Steph H., Orchid Allicock, Mari Armstrong-Hough, and Anne L. Wyllie. ‘Saliva as a Gold-Standard Sample for SARS-CoV-2 Detection’. The Lancet Respiratory Medicine 0, no. 0 (19 April 2021). https://doi.org/10.1016/S2213-2600(21)00178-8.
-
-
-
Merrick, J. (2021, April 20). Covid-19 variants: South African strain is causing the most concern for UK scientists. iNews. https://inews.co.uk/news/politics/covid-19-variants-south-african-strain-is-causing-the-most-concern-for-uk-scientists-965679?utm_term=Autofeed&ito=social_itw_theipaper&utm_medium=Social&utm_source=Twitter#Echobox=1618951521
-
-
www.theguardian.com www.theguardian.com
-
Safi, M. (2021, April 21). India’s shocking surge in Covid cases follows baffling decline. The Guardian. https://www.theguardian.com/world/2021/apr/21/india-shocking-surge-in-covid-cases-follows-baffling-decline
Tags
- variant
- is:news
- surge
- wave
- shortage
- population
- social distancing
- fatality
- COVID-19
- epidemiology
- science
- infection
- oxygen
- india
- public health
- lang:en
- mutation
- delhi
Annotators
URL
-
-
www.theguardian.com www.theguardian.com
-
Beaumont, P. (2021, April 22). Covid-19: India’s response to second wave is warning to other countries. The Guardian. https://www.theguardian.com/world/2021/apr/22/covid-19-india-response-to-second-wave-is-warning-to-other-countries
-
-
blogs.bmj.com blogs.bmj.com
-
Nabavi, N., & Dobson, J. (2021, April 21). Covid-19 new variants—known unknowns. The BMJ Opinion. https://blogs.bmj.com/bmj/2021/04/21/covid-19-new-variants-known-unknowns/?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork
-
-
www.theguardian.com www.theguardian.com
-
Indian expansion of Covid vaccine drive may further strain supplies | India | The Guardian. (n.d.). Retrieved April 19, 2021, from https://www.theguardian.com/world/2021/apr/19/indian-expansion-of-covid-vaccine-drive-may-further-strain-supplies
-
-
-
Gross, A. (2021, April 15). Concerns rise about spread of coronavirus variant in London. https://www.ft.com/content/d1a18cef-68ff-4f37-b5d7-ad522b2bbf68
-
-
www.imperial.ac.uk www.imperial.ac.uk
-
More transmissible and evasive SARS-CoV-2 variant growing rapidly in Brazil | Imperial News | Imperial College London. (n.d.). Imperial News. Retrieved 18 April 2021, from https://www.imperial.ac.uk/news/216053/more-transmissible-evasive-sarscov2-variant-growing/
-
-
en.wikipedia.org en.wikipedia.org
-
The use of U+212B 'Angstrom sign', which was encoded due to round-trip mapping compatibility with an East-Asian character encoding, is discouraged, and the preferred representation is U+00C5 'capital letter A with ring above', which has the same glyph.
Is there a difference in semantic meaning between the two? And if so, what is it? 
-
-
twitter.com twitter.com
-
Trevor Bedford. (2021, January 14). After ~10 months of relative quiescence we’ve started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the SARS-CoV-2 variants of concern emerging from the UK, South Africa and Brazil. 1/19 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1349774271095062528
-
-
docs.microsoft.com docs.microsoft.com
-
How is a pseudoconsole different from a pseudoterminal ?
I'm guessing that's just a Microsoftism to make it easier to search/find things that are specifically about Microsoft's flavor of pseudoterminal.
I see they don't use the word "pseudoterminal" at all, but they do mention
ConPTY, or the Windows PTY
where PTY is another synonym/name for pseudoterminal. So I think we're safe in saying that this is talking about a pseudoterminal.
-
-
stackoverflow.com stackoverflow.com
-
Addendum: seven years later, Windows finally supports pseudoconsoles. If you are running on Windows 10 v1809 or later, this new API should solve your problem.
-
-
www.thelancet.com www.thelancet.com
-
Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., Drew, D. A., Nguyen, L. H., Polidori, L., Selvachandran, S., Hu, C., Capdevila, J., Koshy, C., Ash, A., Wise, E., … Ourselin, S. (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. The Lancet Public Health, 0(0). https://doi.org/10.1016/S2468-2667(21)00055-4
-
-
www.theguardian.com www.theguardian.com
-
UCL team’s claim that herd immunity set to be achieved in UK disputed | Coronavirus | The Guardian. (n.d.). Retrieved April 12, 2021, from https://www.theguardian.com/world/2021/apr/09/ucl-team-claim-covid-19-herd-immunity-achieved-uk-disputed-scientists
-
-
jamanetwork.com jamanetwork.com
-
Rubin, R. (2021). COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough. JAMA, 325(13), 1241. https://doi.org/10.1001/jama.2021.3370
-
-
www.medrxiv.org www.medrxiv.org
-
Lee, L. Y., Rozmanowski, S., Pang, M., Charlett, A., Anderson, C., Hughes, G. J., Barnard, M., Peto, L., Vipond, R., Sienkiewicz, A., Hopkins, S., Bell, J., Crook, D. W., Gent, N., Walker, A. S., Peto, T. E., & Eyre, D. W. (2021). SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. MedRxiv, 2021.03.31.21254687. https://doi.org/10.1101/2021.03.31.21254687
-
-
material-ui.com material-ui.com
-
Note: The standard variant of the TextField is no longer documented in the Material Design guidelines (here's why), but Material-UI will continue to support it.
-
-
medium.com medium.com
-
Enclosed text fields with a rectangular (box) shape performed better than those with a line affordance
-
- Mar 2021
-
bhekisisa.org bhekisisa.org
-
Team, B. (2021, March 29). Why South Africa isn’t using the AstraZeneca jabs it bought. Bhekisisa. https://bhekisisa.org/health-news-south-africa/2021-03-29-why-south-africa-isnt-using-the-astrazeneca-jabs-it-bought/
-
-
www.bloomberg.com www.bloomberg.com
-
Younger Brazilians Are Dying From Covid in an Alarming New Shift. (2021, March 26). Bloomberg.Com. https://www.bloomberg.com/news/articles/2021-03-26/younger-brazilians-are-dying-from-covid-in-an-alarming-new-shift
-
-
www.covid-datascience.com www.covid-datascience.com
-
Covid Data Science. (2021) ‘UK Variant B.1.1.7 becoming the dominant strain in the USA - what does it mean for Spring/Summer?’. Accessed 26 March 2021. https://www.covid-datascience.com/post/uk-variant-b-1-1-7-becoming-the-dominant-strain-in-the-usa-what-does-it-mean-for-spring-summer
-
-
www.krisp.org.za www.krisp.org.za
-
de Oliveira T, Lutucuta S, Nkengasong J, Morais J, Paixao JP, Neto Z, Afonso P, Miranda J, David K, Ingles L, Amilton P A P R R C, Freitas H R, Mufinda F, Tessema K S , Tegally H, San E J, Wilkinson E, Giandhari J, Pillay S, Giovanetti M, Naidoo Y, Katzourakis A, Ghafari M, Singh L, Tshiabuila D, Martin D, Lessells R. (2021) A Novel Variant of Interest of SARS-CoV-2 with Multiple Spike Mutations Detected through Travel Surveillance in Africa. medRxiv. https://www.krisp.org.za/publications.php?pubid=330. Accessed 26 March 2021.
-
-
-
Volz, E., Mishra, S., Chand, M. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature (2021). https://doi.org/10.1038/s41586-021-03470-x
-
-
jamanetwork.com jamanetwork.com
-
Edara, Venkata Viswanadh, William H. Hudson, Xuping Xie, Rafi Ahmed, and Mehul S. Suthar. “Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.” JAMA, March 19, 2021. https://doi.org/10.1001/jama.2021.4388.
-
-
www.theguardian.com www.theguardian.com
-
New coronavirus strain behind a fifth of cases in Norfolk, data shows. (2020, December 15). The Guardian. http://www.theguardian.com/world/2020/dec/15/uk-should-boost-vaccine-programme-to-tackle-covid-variant-says-leading-scientist
-
-
www.lshtm.ac.uk www.lshtm.ac.uk
-
The impact of reopening schools on SARS-CoV-2 transmission in England. (n.d.). LSHTM. Retrieved 10 March 2021, from https://www.lshtm.ac.uk/newsevents/news/2021/impact-reopening-schools-sars-cov-2-transmission-england
-
-
github.com github.com
-
BDI-pathogens/covid-19_instant_tracing. (n.d.). GitHub. Retrieved 13 February 2021, from https://github.com/BDI-pathogens/covid-19_instant_tracing
-
-
twitter.com twitter.com
-
David R Tomlinson 💙. (2021, March 5). Truth. 💙 @FreshAirNHS @theRCN @TheBMA @mancunianmedic @DrLindaDykes @Chakladar_A @KGadhok https://t.co/Ke2C84KuaT https://t.co/C469qvrSoK [Tweet]. @DRTomlinsonEP. https://twitter.com/DRTomlinsonEP/status/1367962251211202566
Tags
- variant
- PHE
- misleading
- advisory bodies
- government
- economic issues
- COVID-19
- is:tweet
- respiratory conditions
- respiratory protection
- PPE
- misinformation
- policy contexts
- scientists
- health and care workers
- SARS-CoV-2
- DHSC
- infections
- lang:en
- care homes
- transmission
- ethical guidelines
- guidance
Annotators
URL
-
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 100; 0.1 µM: 65; 0.8 µM: 18; 1 µM: 15
AssayResultAssertion: Abnormal
Approximation: Exact cisplatin concentrations and assay result values not reported; values estimated from Figures 4b and 4d.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 80; 0.1 µM: 52; 0.8 µM: 18; 1 µM: 5
AssayResultAssertion: Abnormal
Approximation: Exact cisplatin concentrations and assay result values not reported; values estimated from Figures 4b and 4d.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 102; 0.1 µM: 65; 0.8 µM: 18; 1 µM: 10
AssayResultAssertion: Abnormal
Approximation: Exact cisplatin concentrations and assay result values not reported; values estimated from Figures 4b and 4d.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 85; 0.1 µM: 40; 0.8 µM: 20; 1 µM: 13
AssayResultAssertion: Abnormal
Approximation: Exact cisplatin concentrations and assay result values not reported; values estimated from Figures 4b and 4d.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 90; 0.1 µM: 60; 0.8 µM: 15; 1 µM: 15
AssayResultAssertion: Abnormal
Approximation: Exact cisplatin concentrations and assay result values not reported; values estimated from Figures 4b and 4d.
-
p.A1025R is known to disrupt the interaction between the C-terminus of PALB2 and BRCA2
HGVS: NM_024675.3:c.3073_3074delinsCG p.(Ala1025Arg)
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 70; 0.08 µM: 50; 0.8 µM: 40; 8 µM: 15
AssayResultAssertion: Abnormal
Approximation: Exact Olaparib concentrations and assay result values not reported; values estimated from Figures 4a and 4c.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 50; 0.08 µM: 35; 0.8 µM: 25; 8 µM: 10
AssayResultAssertion: Abnormal
Approximation: Exact Olaparib concentrations and assay result values not reported; values estimated from Figures 4a and 4c.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 60; 0.08 µM: 55; 0.8 µM: 40; 8 µM: 15
AssayResultAssertion: Abnormal
Approximation: Exact Olaparib concentrations and assay result values not reported; values estimated from Figures 4a and 4c.
Comment: This variant was used as an abnormal control in other assays in this publication, but it was not specifically designated as a control in this assay.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 65; 0.08 µM: 50; 0.8 µM: 30; 8 µM: 20
AssayResultAssertion: Abnormal
Approximation: Exact Olaparib concentrations and assay result values not reported; values estimated from Figures 4a and 4c.
-
Cells reconstituted with WT-PALB2 showed substantially less sensitivity to olaparib than cells expressing p.A1025R and p.I944N (Fig. 4a). Similar results were observed for cisplatin treatment, although the difference in sensitivity was less pronounced (Fig. 4b). p.L24S, p.L1070P, and p.L35P were also associated with greater sensitivity to olaparib (Fig. 4c) and cisplatin (Fig. 4d) than WT-PALB2.
AssayResult: 0.01 µM: 50; 0.08 µM: 40; 0.8 µM: 20; 8 µM: 15
AssayResultAssertion: Abnormal
Approximation: Exact Olaparib concentrations and assay result values not reported; values estimated from Figures 4a and 4c.
-
WT-PALB2 was associated with robust formation of damage-induced RAD51 foci, whereas the four variants were associated with defective foci formation (Fig. 3d, e).
AssayResult: 1.5
AssayResultAssertion: Abnormal
Approximation: Exact assay result value not reported; value estimated from Figure 3e.
-
WT-PALB2 was associated with robust formation of damage-induced RAD51 foci, whereas the four variants were associated with defective foci formation (Fig. 3d, e).
AssayResult: <1
AssayResultAssertion: Abnormal
Approximation: Exact assay result value not reported; value estimated from Figure 3e.
-
WT-PALB2 was associated with robust formation of damage-induced RAD51 foci, whereas the four variants were associated with defective foci formation (Fig. 3d, e).
AssayResult: 1
AssayResultAssertion: Abnormal
Approximation: Exact assay result value not reported; value estimated from Figure 3e.
-
WT-PALB2 was associated with robust formation of damage-induced RAD51 foci, whereas the four variants were associated with defective foci formation (Fig. 3d, e).
AssayResult: 3
AssayResultAssertion: Abnormal
Approximation: Exact assay result value not reported; value estimated from Figure 3e.
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 0.5
AssayResultAssertion: Abnormal
StandardErrorMean: 0.03
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 0.5
AssayResultAssertion: Abnormal
StandardErrorMean: 0.05
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 0.6
AssayResultAssertion: Abnormal
StandardErrorMean: 0.15
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 0.6
AssayResultAssertion: Abnormal
StandardErrorMean: 0.07
Comment: This variant was reported as c.2145_2146delT p.(Asp715Glufs2), however the numbering implies the deletion of two nucleotides. The deletion of TA, c.2145_2146delTA, gives the reported protein change (p.(Asp715Glufs2), and was assumed to be the intended variant. Use this evidence with caution.
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 0.8
AssayResultAssertion: Abnormal
StandardErrorMean: 0.14
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 0.8
AssayResultAssertion: Abnormal
StandardErrorMean: 0.13
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 1
AssayResultAssertion: Abnormal
StandardErrorMean: 0
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 1.5
AssayResultAssertion: Abnormal
StandardErrorMean: 0.16
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 1.7
AssayResultAssertion: Abnormal
StandardErrorMean: 0.34
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 1.7
AssayResultAssertion: Abnormal
StandardErrorMean: 0.84
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 2.4
AssayResultAssertion: Abnormal
StandardErrorMean: 0.22
Comment: This variant is reported as a potential hypomorphic variant.
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.32
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3.6
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.28
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3.6
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.01
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3.6
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.11
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3.7
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.13
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3.8
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.18
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 3.9
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.04
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.32
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.07
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.16
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.1
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.56
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.02
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.21
Comment: This variant was reported as c.398C>G p.(Ser133Thr), however the given allele from reference sequence is incorrect and does not match the actual sequence at the given position. The opposite nucleotide change, c.398G>C, gives the reported protein change (p.(Ser133Thr)), and was assumed to be the intended variant. Use this evidence with caution.
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.02
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.4
AssayResultAssertion: Indeterminate
StandardErrorMean: 0.09
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.4
AssayResultAssertion: Normal
StandardErrorMean: 0.39
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.5
AssayResultAssertion: Normal
StandardErrorMean: 0.23
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.5
AssayResultAssertion: Normal
StandardErrorMean: 0.16
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.6
AssayResultAssertion: Normal
StandardErrorMean: 0.09
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.6
AssayResultAssertion: Normal
StandardErrorMean: 0.57
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.6
AssayResultAssertion: Normal
StandardErrorMean: 0.57
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.6
AssayResultAssertion: Normal
StandardErrorMean: 0.32
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.13
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.32
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.92
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.06
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.7
AssayResultAssertion: Normal
StandardErrorMean: 0.11
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.8
AssayResultAssertion: Normal
StandardErrorMean: 0.23
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.8
AssayResultAssertion: Normal
StandardErrorMean: 0.79
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.8
AssayResultAssertion: Normal
StandardErrorMean: 0.24
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.8
AssayResultAssertion: Normal
StandardErrorMean: 0.67
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.29
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.93
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.44
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.71
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.01
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.08
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.04
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.49
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.57
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.27
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.32
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 4.9
AssayResultAssertion: Normal
StandardErrorMean: 0.1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 0.6
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 0.08
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 0.15
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 1.01
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 0.58
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 0.32
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5
AssayResultAssertion: Normal
StandardErrorMean: 1.21
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.1
AssayResultAssertion: Normal
StandardErrorMean: 0.56
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.1
AssayResultAssertion: Normal
StandardErrorMean: 0.7
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.1
AssayResultAssertion: Normal
StandardErrorMean: 1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.2
AssayResultAssertion: Normal
StandardErrorMean: 0.39
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.2
AssayResultAssertion: Normal
StandardErrorMean: 0.1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.2
AssayResultAssertion: Normal
StandardErrorMean: 0.33
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.2
AssayResultAssertion: Normal
StandardErrorMean: 0.7
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.3
AssayResultAssertion: Normal
StandardErrorMean: 0.84
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.3
AssayResultAssertion: Normal
StandardErrorMean: 0.46
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.4
AssayResultAssertion: Normal
StandardErrorMean: 0.13
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.6
AssayResultAssertion: Normal
StandardErrorMean: 0.16
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.8
AssayResultAssertion: Normal
StandardErrorMean: 1.15
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 5.8
AssayResultAssertion: Normal
StandardErrorMean: 0.1
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6
AssayResultAssertion: Normal
StandardErrorMean: 0.13
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.2
AssayResultAssertion: Normal
StandardErrorMean: 1.39
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.4
AssayResultAssertion: Normal
StandardErrorMean: 0.45
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.4
AssayResultAssertion: Normal
StandardErrorMean: 0.96
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.5
AssayResultAssertion: Normal
StandardErrorMean: 1.55
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.6
AssayResultAssertion: Normal
StandardErrorMean: 0.05
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.6
AssayResultAssertion: Normal
StandardErrorMean: 0.8
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 6.9
AssayResultAssertion: Normal
StandardErrorMean: 0.35
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 7.1
AssayResultAssertion: Normal
StandardErrorMean: 0.43
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 7.2
AssayResultAssertion: Normal
StandardErrorMean: 0.01
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 7.3
AssayResultAssertion: Normal
StandardErrorMean: 0.08
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 7.5
AssayResultAssertion: Normal
StandardErrorMean: 0.61
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 7.7
AssayResultAssertion: Normal
StandardErrorMean: 0.15
-
Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).
AssayResult: 7.7
AssayResultAssertion: Normal
StandardErrorMean: 0.15
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.3323delA p.(Tyr1108Serfs*16)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.3362delG p.(Gly1121Valfs*3)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.3497delG p.(Gly1166Valfs*25)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.2145_2146delTA p.(Asp715Glufs*2)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.104T>C p.(Leu35Pro)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.751C>T p.(Gln251Ter)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.1653T>A p.(Tyr551Ter)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.2831T>A p.(Ile944Asn)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.71T>C p.(Leu24Ser)
-
A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected
HGVS: NM_024675.3:c.3209T>C p.(Leu1070Pro)
Tags
- Variant:20
- CAID:CA10583351
- ClinVarID:126591
- CAID:CA294144
- CAID:CA395139263
- CAID:CA299799
- Variant:22
- CAID:CA197176
- ClinVarID:142079
- ClinVarID:126669
- CAID:CA299750
- Variant:57
- CAID:CA151249
- Variant:34
- Variant:31
- Variant:92
- CAID:CA269522
- ClinVarID:126590
- Variant:23
- ClinVarID:186029
- Variant:49
- ClinVarID:126674
- ClinVarID:1243
- CAID:CA269483
- ClinVarID:216752
- Variant:86
- Variant:26
- CAID:CA395139751
- Variant:44
- Variant:35
- Variant:42
- CAID:CA166991
- ClinVarID:126630
- CAID:CA331796
- ClinVarID:126761
- ClinVarID:126767
- ClinVarID:232977
- ClinVarID:230665
- ClinVarID:126742
- ClinVarID:126647
- Variant:63
- ClinVarID:241560
- ClinVarID:186939
- Variant:2
- Variant:1
- Variant:29
- Variant:80
- CAID:CA166841
- Variant:76
- CAID:CA348301
- Variant:73
- Variant:46
- Variant:21
- CAID:CA7963617
- CAID:CA288488
- ClinVarID:245657
- CAID:CA288472
- CAID:CA299747
- ClinVarID:185108
- CAID:CA395137415
- Variant:10
- CAID:CA251717
- CAID:CA168501
- CAID:CA191059
- ClinVarID:126716
- CAID:CA269610
- ClinVarID:126682
- Variant:33
- CAID:CA186642
- ClinVarID:126777
- CAID:CA269666
- Variant:15
- CAID:CA190922
- ClinVarID:185069
- Variant:48
- ClinVarID:126709
- ClinVarID:220218
- ClinVarID:126640
- CAID:CA10579994
- CAID:CA7963328
- CAID:CA7963665
- Variant:65
- ClinVarID:143008
- Variant:37
- ClinVarID:142465
- Variant:6
- ClinVarID:126726
- CAID:CA288475
- ClinVarID:126732
- Variant:66
- ClinVarID:232905
- ClinVarID:582957
- CAID:CA10579945
- CAID:CA7963440
- Variant:11
- ClinVarID:126739
- ClinVarID:126731
- FuncAssay:3
- CAID:CA269558
- CAID:CA196291
- ClinVarID:141256
- CAID:CA288386
- CAID:CA288441
- ClinVarID:126747
- ClinVarID:182770
- CAID:CA288460
- Variant:79
- Variant:74
- Variant:27
- CAID:CA10583375
- Variant:4
- Variant:54
- ClinVarID:126779
- ClinVarID:229738
- ClinVarID:126734
- ClinVarID:126782
- Variant:61
- Variant:72
- ClinVarID:657328
- Variant:91
- ClinVarID:141974
- CAID:CA161333
- Variant:84
- CAID:CA151242
- Variant:87
- CAID:CA10583357
- Variant:50
- Variant:58
- ClinVarID:21675
- ClinVarID:183828
- ClinVarID:182774
- CAID:CA395137900
- CAID:CA168538
- CAID:CA294249
- CAID:CA7963488
- ClinVarID:126746
- ValidationControl:Pathogenic
- Variant:88
- ClinVarID:241550
- ClinVarID:126741
- CAID:CA151230
- ClinVarID:188058
- Variant:71
- Variant:32
- Variant:8
- Variant:89
- CAID:CA269654
- ClinVarID:232781
- Variant:19
- Variant:77
- Variant:25
- Variant:12
- Variant:70
- CAID:CA923726356
- Variant:24
- CAID:CA288451
- ClinVarID:480232
- Variant:81
- CAID:CA269551
- ClinVarID:126638
- Variant:69
- Variant:59
- CAID:CA161330
- ClinVarID:141320
- Variant:45
- Variant:30
- ClinVarID:126683
- CAID:CA168427
- Variant:43
- CAID:CA277851
- CAID:CA269663
- CAID:CA151233
- Variant:47
- ClinVarID:186840
- ClinVarID:187262
- FuncAssay:1
- ClinVarID:126755
- Variant:38
- CAID:CA269636
- Variant:9
- ClinVarID:126652
- Variant:83
- Variant:56
- CAID:CA163734
- Variant:85
- ClinVarID:182775
- Variant:52
- ClinVarID:126595
- Variant:7
- CAID:CA10580054
- Variant:55
- CAID:CA288435
- CAID:CA294118
- ClinVarID:136133
- ClinVarID:233127
- CAID:CA161336
- CA923726356
- Variant:16
- CAID:CA7963609
- ClinVarID:128134
- CAID:CA151212
- Variant:78
- CAID:CA190537
- ClinVarID:185273
- Variant:68
- CGType:Variant
- ClinVarID:128138
- Variant:90
- CAID:CA279533895
- CAID:CA339433
- Variant:67
- Variant:36
- CAID:CA161327
- Variant:41
- Variant:18
- CGType:FunctionalAssayResult
- Variant:13
- ClinVarID:126699
- ClinVarID:232317
- Variant:62
- CAID:CA151222
- Variant:28
- CAID:CA269622
- CAID:CA196017
- Variant:53
- ClinVarID:126774
- ClinVarID:225856
- CAID:CA299753
- CAID:CA269625
- CAID:CA193659
- CAID:CA167019
- Variant:17
- Variant:75
- CAID:CA333921
- CAID:CA168345
- CAID:CA169555
- CAID:CA164933
- CAID:CA288398
- ValidationControl:Benign
- CAID:CA7963465
- CAID:CA269619
- FuncAssay:2
- ClinVarID:182773
- ClinVarID:142048
- CG:BulkAnnotation
- Variant:14
- ClinVarID:570698
- ClinVarID:482010
- Variant:60
- Variant:82
- ClinVarID:184941
- Variant:64
- CAID:CA151236
- CAID:CA299737
- ClinVarID:241553
- CAID:CA151239
- ClinVarID:126594
- ClinVarID:128144
- ClinVarID:140850
- CAID:CA167348
- ClinVarID:126613
- CAID:CA16620143
- ClinVarID:126582
- FuncAssay:4
- ClinVarID:241525
- ClinVarID:419370
- CAID:CA279502031
- Variant:3
- ClinVarID:126780
- ClinVarID:141936
- Variant:51
- CAID:CA170010
- Variant:40
- CAID:CA191499
- ClinVarID:230588
- ClinVarID:142504
- ClinVarID:126738
- CAID:CA10580016
- Variant:39
- ClinVarID:126670
- CAID:CA10579934
- CAID:CA269645
- ClinVarID:217917
- Variant:5
Annotators
URL
-